Eli Lilly Non-GAAP EPS of $1.18 misses by $0.29, revenue of $11.44B misses by $680M
by
Contributor since / Followers
Contributor since / Followers
2 months ago
- Eli Lilly press release (NYSE:LLY): Q3 Non-GAAP EPS of $1.18 misses by $0.29.
- Revenue of $11.44B (+20.5% Y/Y) misses by $680M.
- Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%.
- FY24 revenue consensus of $46.22B, EPS consensus of $13.45
-
2024 Guidance
Prior
Updated
Revenue
$45.4 to $46.6 billion
$45.4 to $46.0 billion
(Gross Margin – OPEX(2)) / Revenue:
(reported)
36% to 38%
unchanged
(non-GAAP)
37% to 39%
unchanged
Other Income/(Expense) (reported)
($525) to ($425) million
($425) to ($325) million
Other Income/(Expense) (non-GAAP)
($400) to ($300) million
unchanged
Tax Rate
Approx. 15%
Approx. 17%
Earnings per Share (reported)
$15.10 to $15.60
$12.05 to $12.55
Earnings per Share (non-GAAP)
$16.10 to $16.60
$13.02 to $13.52